Kim A. Papp, MD, PhD, FRCPC

K. Papp Clinical Research
135 Union Street East
Waterloo, Ontario, Canada
N2J 1C4
519-579-9535

Specialty: Dermatology

Research Interests: Psoriasis, Psoriatic Arthritis, Acne, Actinic Keratoses, Atopic Dermatitis (Eczema), Basal Cell Carcinoma, Onychomycosis, Seborrheic Dermatitis, Vaccines

Dr. Kim Papp is a Member of the College of Physicians and Surgeons of Ontario, a Fellow of the Royal College of Physicians and Surgeons of Canada, and an American Board of Dermatology Diplomate. The Waterloo, Ontario, Canada based dermatologist has over 20 years' experience as a Principal Investigator, and has conducted over 130 psoriasis studies in which he closely supervised and assessed over 2750 subjects. Dr. Papp is an internationally renowned Key Opinion Leader in psoriasis research who conducts clinical trials on a wide range of dermatological disorders.

Dr. Papp, with the support of Probity Medical Research, an organization for which he serves as Founder and President, has earned the distinction of top enrolling investigator in over 70 international dermatology studies.

Dr. Papp has conducted early through late phase psoriasis studies, and has been instrumental in the investigation and development of the following compounds:

adalimumab (Humira®), AIN457, alefacept, AMG714, AMG827, apremilast (CC-10004), BIRB 796 BS, BIRT 2584XX, BMS-582949, briakinumab (ABT-874), CD 2027, clobex, CP-690,550, CRx-140, cyclosporine, dovobet, dovonex, efalizumab, etanercept, golimumab, ILV094, infliximab, KH 1650, MEDI-507, MEDI-545, methotrexate, onercept, recombinant human interleukin eleven (rhIL-11), roziglitazone maleate, RWJ-445380,tacrolimus, tazorac, tofacitinib (CP-690, 550), ustekinumab (CNTO1275), volclosporine (ISA247)

K. Papp Clinical Research, like many high-enrolling research sites, has had routine inspections by the Food and Drug Administration, Health Canada, and the European Medicines Agency. Dr. Papp's clinic has the unique distinction of producing no significant findings; the FDA's Form 483—a standard document issued to non-compliant research centres—has never been issued to K. Papp Clinical Research.

Dr. Papp has acted as consultant and/or advisor to over 40 pharmaceutical companies on the development of dermatological compounds. He is instrumental in improving and refining study designs, and serves on a number of Steering Committees and Advisory Boards tasked with developing effective and efficient strategies for the timely development of new treatments. An author on over 275 publications, and a highly sought-after speaker known for delivering engaging, thought-provoking and accessible presentations, Dr. Papp is held in the highest esteem by the academic and medical communities.

Here is the disclosure statement from a February 2015 paper on Enbrel with Kim Papp, M.D. as lead author:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340046/

K.A.P. is a consultant, speaker, or investigator for AbbVie, Amgen Inc., Astellas, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Merck (MSD), LEO Pharma, Novartis, and Pfizer.

Of the 9 other authors, two work for Papp's Probity Medical: C.W. Lynde and J. Toole, each of whom has their own ties to Amgen etc. etc. Three are Amgen employees, and three of the other four have conflict statements like Papp's.

For a Sept. 2015 Humira paper, he states:

http://www.jaad.org/article/S0190-9622(15)01817-4/abstract

Dr Papp received honoraria or grants from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa, Leo Pharma, Merck, Novartis, and Pfizer for participation on advisory boards, and for participation as a consultant and investigator.

Three of his co-authors are AbbVie employees, and the other three have conflict statements like his.

Here's how the study was run:

AbbVie funded this registry and participated in the design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication. All authors were also involved in the decision to submit the manuscript for publication, and had the right to accept or reject comments or suggestions. A medical writer employed by AbbVie participated in the writing of this manuscript, and is acknowledged.

The lead author of the Humira paper, Martin Menter, is an American who can be checked on Open Payments.

https://openpaymentsdata.cms.gov/physician/137563

In 2014 he pulled in $969,096.43 in research grants -- and accepted $158,196.16 in "general payments" to himself.